Your browser doesn't support javascript.
loading
Incorporating patient generated health data into pharmacoepidemiological research.
Bourke, Alison; Dixon, William G; Roddam, Andrew; Lin, Kueiyu Joshua; Hall, Gillian C; Curtis, Jeffrey R; van der Veer, Sabine N; Soriano-Gabarró, Montse; Mills, Juliane K; Major, Jacqueline M; Verstraeten, Thomas; Francis, Matthew J; Bartels, Dorothee B.
Afiliação
  • Bourke A; Real World Solutions, IQVIA, London, UK.
  • Dixon WG; Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, UK.
  • Roddam A; Data & Computational Sciences, GSK, London, UK.
  • Lin KJ; Brigham and Women's & Department of Medicine, Boston, Massachusetts, USA.
  • Hall GC; Gillian Hall Epidemiology Ltd, London, UK.
  • Curtis JR; Division of Clinical Immunology & Rheumatology, The University of Birmingham, Birmingham, Alabama, USA.
  • van der Veer SN; Centre for Health Informatics, Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.
  • Soriano-Gabarró M; Bayer AG, Berlin, Germany.
  • Mills JK; PRA Health Sciences, Raleigh, North Carolina, USA.
  • Major JM; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Verstraeten T; P95 Pharmacovigilance and Epidemiology, Leuven, Belgium.
  • Francis MJ; The Procter & Gamble Company, Cincinnati, Ohio, USA.
  • Bartels DB; UCB Pharma, Anderlecht, Belgium.
Pharmacoepidemiol Drug Saf ; 29(12): 1540-1549, 2020 12.
Article em En | MEDLINE | ID: mdl-33146896
ABSTRACT
Epidemiology and pharmacoepidemiology frequently employ Real-World Data (RWD) from healthcare teams to inform research. These data sources usually include signs, symptoms, tests, and treatments, but may lack important information such as the patient's diet or adherence or quality of life. By harnessing digital tools a new fount of evidence, Patient (or Citizen/Person) Generated Health Data (PGHD), is becoming more readily available. This review focusses on the advantages and considerations in using PGHD for pharmacoepidemiological research. New and corroborative types of data can be collected directly from patients using digital devices, both passively and actively. Practical issues such as patient engagement, data linking, validation, and analysis are among important considerations in the use of PGHD. In our ever increasingly patient-centric world, PGHD incorporated into more traditional Real-Word data sources offers innovative opportunities to expand our understanding of the complex factors involved in health and the safety and effectiveness of disease treatments. Pharmacoepidemiologists have a unique role in realizing the potential of PGHD by ensuring that robust methodology, governance, and analytical techniques underpin its use to generate meaningful research results.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacoepidemiologia / Dados de Saúde Gerados pelo Paciente Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Farmacoepidemiologia / Dados de Saúde Gerados pelo Paciente Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article